Skip to content

Human and Bacterial Protease Activity As Prognostic Tool of Foot Infections in Diabetic Patients

Human and Bacterial Protease Activity As Prognostic Tool of Foot Infections in Diabetic Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03964571
Acronym
CHEK BAC
Enrollment
61
Registered
2019-05-28
Start date
2019-10-09
Completion date
2024-12-13
Last updated
2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Infection

Brief summary

This study will establish whether human and bacterial protease activity can aid therapeutic decision-making, including targeted treatments.

Interventions

DIAGNOSTIC_TESTWOUNDCHEK

fluid swab of wound and measurement of wound onto film

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient has been informed about the study objectives and purpose and their rights as a patient * The patient is being treated in the Diabetes and Infectious Disease Department * The patient has a chronic foot and/or heel wound classified as Grade 1-3 according to the Infectious Diseases Society of America.

Exclusion criteria

* The subject is participating in another category I interventional study, or has participated in another category I interventional trial in the previous 3 months, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The patient is pregnant or breastfeeding * The patient has chronic foot and/or heel wound classified as Grade 4 according to the Infectious Diseases Society of America * Patient with critical ischemia defined by PSGo \<50 mmHg or PSCh \<70 mmHg

Design outcomes

Primary

MeasureTime frameDescription
Reduction in size of woundFrom Day 0 to week 4% change in surface area of wound; traced on OpSite Flexigrid ® film

Secondary

MeasureTime frameDescription
Presence of elevated protease activity in foot woundDay 0Binary Yes/No; WOUNDCHEK™ Protease Status
Presence of bacterial protease activity in foot woundDay 0, 14 and 28Binary Yes/No; WOUNDCHEK™ Bacterial Status
Clinical exam of woundDay 0Classification as either infection or colonization according to Infectious Diseases Society of America classification
Presence of pathogenic bacteria in woundDay 0Wound swabs cultured and bacteria identified
Reduction in size of woundFrom Day 0 to Week 2% change in surface area of wound; traced on OpSite Flexigrid ® film

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026